GP30341

GP30341 is an investigational drug developed by GEROPHARM LLC, Russia, currently being studied for its pharmacokinetics, safety, and efficacy in healthy volunteers and patients with COVID-19 who are at high risk of adverse outcomes. The drug is administered as 200 mg capsules. The clinical development program includes two stages: first, an open non-comparative study in healthy volunteers to assess pharmacokinetics and safety at different dosing regimens; second, an open randomized study comparing GP30341 to standard therapy in COVID-19 patients with a high risk of adverse outcome[1][2][3]. The mechanism of action has not been explicitly described in available sources.